APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported resilient Q4 FY26 results with revenue of Rs. 1,848 Cr (up 4% YoY) and net profit of Rs. 203 Cr (up 29% YoY). EBITDA pre-R&D stood at Rs. 455 Cr with a 25% margin. All key segments showed growth: India Branded Business grew 4% to Rs. 568 Cr, US Formulations rose 11% to Rs. 564 Cr, and API business increased 2% to Rs. 347 Cr. The company made a strategic entry into the US Branded Pharmaceuticals market with the launch of Pivya, an antibiotic for uncomplicated urinary tract infections. For the full year FY26, total revenue grew 10% to Rs. 7,345 Cr. The company received 4 ANDA approvals and launched 6 products in the US market during Q4.
Strong profit growth of 29% YoY with stable margins indicates improved operational efficiency. The entry into US Branded Business opens a new growth avenue. The 10% full-year revenue growth reflects solid execution across all business segments.